Mark Weinberg has spent more than 17 years as a pharmaceutical and biotech executive with experience ranging from “top 20” pharma companies to micro-cap biotech.
He has worked with the FDA and EMA on discussions about drug candidate development and regulatory issues in multiple therapeutic areas, from pre-IND (Investigational New Drug) to New Drug Application/Biologics License Application (NDA/BLA).
He has also worked on multiple partnered development programmes.
Dr Weinberg joins Avillion from Halloran Consulting Group, where he was Chief Medical Officer and Managing Director. Halloran is consulting firm that provides strategic guidance and development expertise to life science companies.
Prior to that, Weinberg was Senior Vice President of Clinical Development at US biotech company RestorGenex Pharmaceuticals. Previously, he worked at Astellas Pharma Global Development. He was Vice President, Global Clinical Science and also Global Therapeutic Area Head, CNS and Pain.
Weinberg has held various positions of increasing responsibility at Lundbeck Inc. (formerly Ovation Pharmaceuticals), Takeda Global Research and Development and Abbott Laboratories.
He earned his MD from Duke University and remained there to complete a residency in internal medicine. He also holds an MBA from the Kellogg Business School and a BA in economics from Yale University.
Allison Jeynes-Ellis, Chief Executive Officer of Avillion, said: “It is a great pleasure to welcome Mark to our management team at Avillion. He brings extensive pharmaceutical development skills and experience that will help us meet our objective to successfully deliver robust, high quality clinical data to pharma clients whilst accelerating their programmes.”
